(PharmaNewsWire.Com, August 24, 2021 ) Humanized Mouse Model Market size was valued at $83.29 million in 2020, and is anticipated to reach $86.98 million by the end of 2026 growing at a CAGR of 8.2% during the forecast period 2021-2026. The humanized mouse model industry growth rate is attributed to the growing incidences of chronic disorders and increasing demand for effective therapeutic drugs and is anticipated bringing new opportunities. Basic science, safety evaluation for large molecule therapeutics, simulation of some human-specific infectious diseases, and efficacy testing of immunotherapy approaches all use humanised mouse models. In both cells and tissues, the human protein is expressed, while the mouse protein is silenced. Humanized mouse models are used to study cancer genetics, Auto immune diseases, regenerative medicine, human hematopoiesis, infectious diseases, transplantation, and autoimmunity. They improve the translational value of preclinical research by allowing researchers to gain a better understanding of disease pathways. Apart from this, the model requires accurate risk assessment and thorough analysis to preserve the physiological expression and regulation of the human gene inserted into the mouse genome. The genes and proteins of both the mouse and the human are examined for accuracy and structure in order to determine the optimum expression and functionality of the human protein in a mouse environment. Nonetheless, speedy technological advancements have been seen in the area, leading to the development of transgenic mouse, knock-in mouse, and knock-out mouse.
Humanized Mouse Model Market Segment Analysis - By Application
In 2020, on the basis of application, oncology segment accounted for the largest segmental revenue of the humanized mouse model market. The oncology segment held the largest market on account of the rising number of cancer research activities. This segment is projected to witness healthy growth throughout the forecast period 2021-2026 with a CAGR of 8.80%. This is owing to its vast range of applications in a variety of oncological fields coupled with advanced healthcare facilities and growing healthcare expenditure. Furthermore, there is an increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research. All these factors are anticipated to fuel market growth during the forecast period 2021-2026.
Humanized Mouse Model Market Segment Analysis - By End Users
On the basis of end users, contract research organizations (CROs) segment accounted for the largest segmental revenue of the humanized mouse model market in 2020. The largest share can be attributed to the rise in the number of pharmaceutical companies outsourcing their preclinical studies to CROs. In addition, contract research organisations (CROs) are focusing on using these models to produce new drugs in order to gain a profitable market share. They are also interested in drug toxicity assessment and preclinical analysis. Furthermore, biotechnology corporations fund basic and advanced medical and veterinary research programs.
On the other hand, academic & research institutes segment is projected to dominate over the forecast period 2021-2026 with a CAGR of 8.50%. Owing to the rising demand for mice models in academic institutions, academic and research institutes are expected to expand at a healthy rate. For pharmacology education, academic institutions use preserved mice models to understand drug toxicity behavior. In addition, these models are being used in academia to educate and prepare a new generation of scientists and facility managers. Yale University, for example, created a novel HIV drug that suppressed the HIV virus in humanised mice and was found to be less toxic. The University of Pittsburgh and Temple University conducted a related study to exclude HIV DNA from the genomes of humanised mice. Both of these factors would contribute to the growth of the segmental market.
Humanized Mouse Model Market Segment Analysis - By Geography
North America is the major region dominating the Humanized Mouse Model market with a market share of 35.60% in the year 2020. This can be attributed to the growth in this regional segment and can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada have fueled the regional market. Moreover, increasing number of research and development activities with increasing need for early-stage diagnose of various types of cancer & cardiovascular diseases are also driving regional market growth.
However, Asia-Pacific is projected to be the significant-growing market growth CAGR during the forecast period 2021-2026. This is owing to foreign R&D partnerships in China, which include measures to shorten drug approval times and mandate animal testing for both prescription drugs and cosmetics, resulting in increased government and private sector investment in China's life sciences sector. Apart from these, the creation of bio-clusters to boost India's biotechnology, growth in translational and biomedical research in Singapore, increase in animal research in Malaysia, and ongoing biomedical research activities in Australia are all expected to drive the market in the area.
The humanized mouse model market is poised to receive upswing owing to the rising demand for personalized medicine as these medicines are designed through the use of animal models, particularly mice models. Human tissues are transplanted into immune-deficient models, and the disease expression is registered. Following that, the model is treated with a variety of drugs or gene therapies in order to find the most appropriate therapy, resulting in appropriate or customized medication for patients and thereby augmenting factors that will impact the global market. Furthermore, advancements in genomics, proteomics, and metabolomics; the completion of the Human Genome Project; the growth of tailored diagnostics and therapeutics; and the increasing focus on wellbeing, wellness, and prevention are all driving demand for personalised medicine.
Humanized Mouse Model Market Challenges
High Cost Of Humanized Models
Despite several drivers, one of the major factor hindering is the high cost of humanized models which is restraining the its usage in experiments as humanized models used in experiments can cost thousands of dollars even in the case of a single patient. Moreover, using humanized models in government-funded basic research can also be cost-prohibitive thereby, challenging the regional market growth.
Humanized Mouse Model Market Landscape
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Humanized Mouse Model Market. In 2020, Humanized mouse model market share is fragmented by the top ten players present in the market. The humanized mouse model market top 10 companies are The Jackson Laboratory, Taconic Biosciences, Inc., Harbour BioMed, HuMurine Technologies, Inc., Vitalstar Biotechnology Co. Ltd., Crown Bioscience, Inc., ingenious targeting laboratory, Axenis S.A.S., TRANS GENIC, Inc., genOway S. A. and others.
Acquisitions/Product Launches
In April 2019, Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the launch of TruBIOME®, a first of its kind solution enabling the generation and maintenance of mice with custom microbiome profiles.
Key Takeaways
North America dominated the Humanized Mouse Model market with a share of 35.60% in the year 2020.
The factors such as growing aging population and rising number of diagnostic imaging are amongst the major factor projected to impel growth of Humanized Mouse Model market.
Additionally, factors such as development of automated diagnostic imaging systems for laboratories and hospitals to provide efficient, accurate, and error-free diagnosis and increasing government investments are to create opportunities paving a way for the growth in the market during forecast period 2021-2026.
For more Lifesciences and Healthcare related reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
